By Drug Target Review2025-10-31T08:30:24
Scientists have discovered that two existing pain medications – bupivacaine and rimegepant – may not only relieve the severe pain caused by osteosarcoma but also slow the disease’s growth.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2025-08-05T13:42:00
Sponsored by ICON plc., By Drug Target Review
2025-11-13T14:00:00
Sponsored by Cell Signaling Technology
2026-03-11T14:00:00
Sponsored by Merck
2023-03-28T11:38:32
Sponsored by Bio-Techne
2025-07-30T08:00:00
Sponsored by Wuxi Biologics
2023-11-20T13:43:43
Sponsored by Merck
Site powered by Webvision Cloud